A Close Look at the Evidence on Low-Intensity Shockwave Therapy in Erectile Dysfunction — A Systematic Review and Meta-Analysis of Randomized Controlled Trials

LI-ESWT improved IIEF scores across 19 RCTs, but most studies failed to reach the minimally clinically important difference

Journal: The Journal of Sexual Medicine | Published: 2026-03-07 | Type: Systematic Review, Meta-Analysis | PMID: 41894473 Authors: You Chia-Hao et al. — Taoyuan Armed Forces General Hospital and Wan Fang Hospital / Taipei Medical University, Taiwan Funding/COI: Not listed for either

Summary

Low-intensity extracorporeal shockwave therapy has been generating buzz as a non-invasive ED treatment, and this meta-analysis of 19 RCTs confirms it moves the needle on erectile function scores — statistically speaking. The catch: most of those improvements didn't clear the minimally clinically important difference, the threshold that separates a real-world benefit from a number that looks good in a table. The authors conclude that whether LI-ESWT provides clinically meaningful benefit remains, at present, unclear.

Claims

• Pooled analysis of 19 RCTs showed statistically significant improvements in IIEF scores at 1-month, 3-month, and 6-month follow-ups
• Majority of included studies failed to achieve the minimally clinically important difference on IIEF-EF
• Meta-regression identified treatment frequency and total pulse number per course as factors associated with therapeutic response
• No definitive conclusions possible regarding superiority of any specific treatment protocol
• Confidence in long-term effects reduced by limited 6-month outcome data

Study Quality

This is a methodologically disciplined review. The team pre-registered on PROSPERO (CRD42024581998), searched four databases including ClinicalTrials.gov through October 2024, followed PRISMA, and used the Cochrane RoB 2 tool for bias assessment. Conducting subgroup and meta-regression analyses to chase down the source of heterogeneity is the right approach when treatment protocols vary as much as they do in LI-ESWT literature.

The bigger quality problem is the underlying trial pool, not this review. Most included RCTs had notable methodological limitations — chief among them failing to use the IIEF-EF (6-item domain) as the standardized outcome measure. That inconsistency is exactly why pooling these studies is difficult and why the meta-regression findings about protocol parameters should be treated as hypothesis-generating rather than conclusive.

Red Flags

• Funding and conflicts of interest not disclosed for the review itself — a glaring omission in a field where device manufacturers have obvious commercial stakes
• The underlying RCTs are themselves methodologically weak; a well-conducted meta-analysis of poorly designed trials still produces uncertain results
• Limited 6-month follow-up data means long-term durability is an open question
• Heterogeneous treatment protocols (varying frequency, pulse counts, probe types) make cross-study comparisons unreliable
• Statistically significant ≠ clinically significant — the paper's own conclusion acknowledges the field may be chasing p-values

Strengths

• Honest about the gap between statistical and clinical significance — doesn't oversell the findings
• Pre-registered protocol limits outcome-switching risk
• Thorough database search including grey literature via ClinicalTrials.gov
• Meta-regression attempting to identify optimal protocol parameters is a useful contribution even if the conclusions are tentative
• Cochrane RoB 2 assessment adds credibility to the quality evaluation

Verdict

The most valuable thing about this paper is what it doesn't claim. In a field plagued by overenthusiastic device promotion and underpowered trials, these authors looked at 19 RCTs and said the quiet part loud: the numbers improve, but most studies don't demonstrate a benefit patients would actually feel. That's a responsible read of the evidence. The missing funding and COI disclosures are a problem — this is a commercially active area and transparency matters — but the analysis itself is solid. File this one as a useful corrective to the hype, not a verdict on the therapy.